Johnson & Johnson’s $5.5 Billion Talc Deal Aims to End 76,000 Cancer Claims

In a settlement of thousands of cases claiming its talc products, including baby powder, cause ovarian cancer, Johnson & Johnson said on July 27 that it will pay about $5.5 billion. A tense legal dispute that has plagued the firm for ten years may finally come to a close with this historic transaction. The settlement, according to J&J, encompasses approximately 76,000 claims, which include those in state court as well as those consolidated in federal court in New Jersey.

Accordingly, it stands for the vast majority of the outstanding talc claims against the business. J&J had previously reached settlements in the majority of the cases claiming that mesothelioma was caused by asbestos in their talc. Legal counsel for the plaintiffs verified the settlement on July 27th, praising it as a satisfactory end to the case's ten-year legal saga. Final approval from 95% of ovarian cancer plaintiffs in federal or state court is required for the arrangement to be finalised.

Claims Are Meritless: J&J’s VP Haas

Erik Haas, VP of litigation at J&J, called the claims "meritless" and stated that the business was prepared to settle for the sake of closure. Haas stated that although the firm is certain that the company would have succeeded in the end through additional litigation, as it has done in most cases that have been tried thus far, it chose not to pursue it. Nevertheless, with this settlement in place, the firm can move forward with its aim to provide life-saving drugs and technology. Payments of $3 billion are anticipated by J&J in 2027, with additional payments scheduled for 2028.

However, the amount of the transaction could increase based on the number of participants in the settlement. J&J might end up paying $7 billion or more, according to Chris Seeger, an attorney who helped negotiate the deal and represents over 2,500 plaintiffs with talc claims. He clarified that while the settlement does cap J&J's total payout, it does give precise sums to qualified ovarian cancer claims. "Our clients are going to be happy with it," Seeger stated, adding to his earlier statement that they got a fair payment.

J&J Always Denied the Cancer Claims

For a long time, J&J has argued that their talc products were completely safe and did not include any asbestos, thereby denying any link to cancer. After making the switch to a cornflour product in 2020, the firm ceased distributing talc-based baby powder in the US. After being paused for over three years, the litigation was eventually revived in March 2025. To try and resolve the charges, J&J filed three bankruptcies using a shell company subsidiary, a practice known as the "Texas two-step", but it was unsuccessful.

All of the bankruptcies resulted in termination. Prior to its bankruptcy filings, J&J had a chequered history in talc trials, including a multimillion dollar ruling in favour of 22 women who claimed that baby powder was the cause of their ovarian cancer. A few trials the corporation won hands down, while others saw their verdicts reduced on appeal.

The new arrangement does not deal with future litigation, unlike the planned bankruptcy settlements, and it is limited to current claims. More funds were available to present litigants due to the exclusion of future claims than were available according to the bankruptcy proposal. Additionally, according to Seeger, it speeds up the payments so that all claims will be paid within 18 months instead of over a decade.